**Supplemental table 1 . Differences between total REDUCE group, total long-term follow-up group, responders and non-responders**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | **Original**  **group**  **N=1789** | **Total**  **long term group**  **N= 1245** | **Responders**  **N=887** | **Non-responders**  **N=358** |
| *Intervention versus control group* |  |  |  |  |
| Haloperidol group  Placebo group | 1082 (60)  707 (40) | 771 (62)  473 (38) | 557 (63)  330 (37) | 214 (60)  144 (40) |
| *Patient variables* |  |  |  |  |
| Age in years, mean ± SD | 67 ± 13 | 66 ± 13 | 66 ± 13 | 67 ± 12 |
| Male/Female, n (%) | 1099/690 (61/39) | 772/473 (62/38) | 566/321 (64/36) | 206/152 (57/43) |
| *ICU variables* |  |  |  |  |
| Admission type Surgical  Medical  Trauma | 828 (46)  893 (50)  68 (4) | 666 (54)  526 (42)  53 (4) | 475 (54)  369 (41)  43 (5) | 191 (53)  157 (44)  10 (3) |
| Mechanically ventilated, n (%) | 940 (76) | 940 (76) | 660 (74) | 280 (78) |
| APACHE II score, mean ± SD | 19 ± 7 | 19 ± 7 | 19 ± 7 | 19 ± 7 |
| Length of stay ICU, median [IQR] | 4 [2-9] | 4 [2-10] | 5 [2-10] | 4 [2-9] |
| Length of stay hospital, median [IQR] | 15 [9-28] | 16 [10-30] | 17 [10-31] | 14 [8-25] |
| *Outcome variables* |  |  |  |  |
| Incidence of delirium at 28 days, n (%) | 616 (35) | 480 (39) | 349 (39) | 131 (37) |
| Alive at 28 days, n (%) | 1481 (83) | 1044 (84) | 755 (85) | 289 (81) |
| Alive at 90 days, n (%) | 1410 (79) | 995 (80) | 718 (81) | 277 (77) |